Frontier Biotechnologies Inc.

SHSE:688221 Stock Report

Market Cap: CN¥5.9b

Frontier Biotechnologies Management

Management criteria checks 3/4

Frontier Biotechnologies' CEO is Dong Xie, appointed in Jan 2002, has a tenure of 23.67 years. directly owns 3.72% of the company’s shares, worth CN¥219.42M. The average tenure of the management team and the board of directors is 9.6 years and 8.5 years respectively.

Key information

Dong Xie

Chief executive officer

CN¥2.2m

Total compensation

CEO salary percentagen/a
CEO tenure23.7yrs
CEO ownership3.7%
Management average tenure9.6yrs
Board average tenure8.5yrs

Recent management updates

Recent updates


CEO

Dong Xie (59 yo)

23.7yrs
Tenure
CN¥2,242,700
Compensation

Dr. Dong Xie, Ph D founded Frontier Biotechnologies Inc. in 2002 and serves as its Chairman and Chief Scientific Officer since January 2013 and serves as its President since 2025. Prior to co-founding Fron...


Leadership Team

NamePositionTenureCompensationOwnership
Dong Xie
Founder23.7yrsCN¥2.24m3.72%
CN¥ 219.4m
Qi Shao
Senior VP9.6yrsCN¥1.27mno data
Rongjian Lu
CTO & Director12.7yrsCN¥2.03m5.8%
CN¥ 342.7m
Hangzhou Lv
Senior Vice President of Marketing & Salesno dataCN¥1.15mno data
Changjin Wang
MD, CBO & Directorless than a yearCN¥2.21m5.62%
CN¥ 331.9m
Qianya Gao
VP, Deputy GM & Secretary of the Board of Directors4.8yrsCN¥919.20kno data
Xin Guan
Accounting Supervisorno datano datano data
Yuting Zhu
Supervisor & Deputy GM of Administrationno dataCN¥593.80kno data
Michael Hu
C.M.O.no datano datano data
Michael Wang
Senior Vice President & Head of Infectious Diseases Therapy Areano datano datano data
9.6yrs
Average Tenure
55yo
Average Age

Experienced Management: 688221's management team is seasoned and experienced (9.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dong Xie
Founder12.7yrsCN¥2.24m3.72%
CN¥ 219.4m
Rongjian Lu
CTO & Director12.7yrsCN¥2.03m5.8%
CN¥ 342.7m
Changjin Wang
MD, CBO & Director12.7yrsCN¥2.21m5.62%
CN¥ 331.9m
Yuting Zhu
Supervisor & Deputy GM of Administration6.6yrsCN¥593.80kno data
Yuantao Cao
Supervisor7.3yrsno datano data
Zhi Zhong Jiang
Chairman of the Supervisory Board & Purchasing Director9.6yrsCN¥380.60kno data
Yuanfan Chen
Director1.6yrsno datano data
Qidong You
Independent Directorless than a yearno datano data
8.5yrs
Average Tenure
51.5yo
Average Age

Experienced Board: 688221's board of directors are considered experienced (8.5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/22 16:56
End of Day Share Price 2025/09/22 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Frontier Biotechnologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.